Track record · closed signal

Boston Scientific Corporation (BSX) — closed signal from July 8, 2025

Partial Published before the outcome was known, scored automatically when the window closed on October 6, 2025.

Predicted vs. what happened

BSX price · publication thesis → realized outcomesplit-adjusted
$102.25 Published $120.66 Target $96.70 Window close $109.50 Peak
$99.00 – $103.00Entry zone — fair-value band
$102.25Published — price the day we called it
$120.66Target — the price the thesis aimed for
$109.50Peak — highest point inside the window, not a realized return
$96.70Window close — end-of-window price, context only

What happened

Partial

Reached 39% of the predicted growth at its peak, without hitting the target.

Peak price
$109.50
peak on September 9, 2025 — not a realized return
Peak gain
+7.1%
peak, from the publication price
Window close
$96.70
end-of-window price, context only
Days to target
—
Window
July 8, 2025 – October 6, 2025

The thesis — published July 8, 2025

Predicted growth
+18%
over the measurement window
Target price
$120.66
the price the thesis aimed for
Entry zone
$99.00 – $103.00
the fair-value band we waited for
Price at publication
$102.25
published July 8, 2025
Confidence
78%
how strongly the data lined up
Timeframe
Short-term (0–3 months)

Boston Scientific’s share price is resting just above an important long-term price level. The FDA has cleared its FARAPULSE heart device for wider use, adding about $700 million in possible yearly sales. Major brokerages reaffirmed a $115 goal, and a positive sector call adds momentum. Trading volume usually bounces in autumn, so the stock could rise 15-20 % over the next quarter with manageable risk.

Primary drivers

  • New FDA approval could add roughly $700M in yearly sales from extra heart procedures.
  • Price sits above a key long-term line, a sign that buyers are still in charge.
  • TD Cowen held a $115 target and more analysts turned positive this week.
  • Heart-related procedures bounce back in Q3, which often boosts device makers.

How it played out

BSX: target was not reached inside the window

Lyra published BSX at $102.25 on July 8, 2025. The thesis expected 18% growth in a short-term window, with a target of $120.66. It pointed to wider FDA clearance for FARAPULSE, possible yearly sales of about $700 million, support near a long-term price level, a $115 brokerage target, more positive analyst tone, and a Q3 rebound in heart-related procedures.

Inside the window, BSX rose but did not reach the target. The peak was $109.5 on September 9, a 7.1% gain. It never got there. By October 6, it ended at $96.7. The thesis partially played out on direction at the peak, but it missed the published target and finished below the publication price.

What happened during the window

On July 23, 2025, Investor's Business Daily reported that Boston Scientific posted second-quarter results, raised its 2025 outlook, and said FARAPULSE U.S. growth was 117%. The same report said BSX closed at $107.77 that day.

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Share this receipt

A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All BSX signals